Friday 28 February 2014

Investigation Report on China Quetiapine Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Quetiapine Market, 2009-2018. Schizophrenia is a common mental disorder. As a chronic disease, schizophrenia can lead to recurrent or persistent symptoms in most patients' whole life. As Chinese economy and society develops, life and work here has become increasingly stressful. As a result, recurrence rate of schizophrenia has also increased. Statistics shows that the number of schizophrene in China has exceeded 10 million by the end of 2013, and it is still rising year after year.
Quetiapine is originally developed by Astra Zeneca and has curative effect on various schizophrenic symptoms. It was firstly approved to the U.K. market in July 1997 and to the U.S. market on September 26, 1997 by FDA with the trade name "Seroquel". Patent of this product expired on March 26, 2012. To prolong its life cycle, long-acting release formulation of quetiapine developed by Astra Zeneca was approved to the U.S. market on May 17, 2007 with the trade name "Seroquel XR", which extends its patent protection to November 28, 2017. After that it has come into markets of several countries sequentially, such as Germany and China.
In 2012, global sales revenue of Seroquel and Seroquel XR was USD 2,803 million, of which the former dropped by 70% to USD 1,294 million while the later increased to USD 1,509 million.
The moment the patent of Seroquel expired, it became target of many generic drug manufacturers.
On March 22, 2012, the U.K. High Court ruled that the patent of Seroquel XR prescription was invalid. However, District Court of New Jersey later ruled that patent of Seroquel XR was valid. Consequently, the production of Seroquel generic drug by Anchen, Osmotica, Torrent and Mylan Pharmaceutical Company has violated the patent of Seroquel XR prescription, which expires in 2017.
On March 27, 2012, Teva Pharmaceutical Industries Limited launched generic drugs of Seroquel and Seroquel XL in the U.K. on the same day, Dr. Reddy's Lab from India launched Seroquel generic drug in the U.S. Astra Zeneca permitted Intelli to sell generic drug of Seroquel XL from November 2016.
Quetiapine produced by Astra Zeneca was approved to China in 2000 with the trade name "Seroquel". In the same year, Hunan Dongting Pharmaceutical Co., Ltd. became the first approved manufacturer to produce quetiapine raw material and troche with the brand name "Qi Wei". In 2003, Suzhou Pharmaceutical Group Co., Ltd. was also approved to produce quetiapine raw material and troche with the brand name "Shu Si". Moreover, Chongqing Fuan Pharmaceutical Co., Ltd. and Zhejiang Supor Pharmaceuticals Co., Ltd. received raw material approvals respectively in 2011 and 2012. Many pharmaceutical manufacturers in China have reported quetiapine tablet production, among which Suzhou Pharmaceutical Group Co., Ltd. reported the production of quetiapine sustained-release tablets in 2012.
According to investigation, Seroquel produced by Astra Zeneca takes up over 70% of quetiapine market in Chinese sample hospitals, followed by Qi Wei produced by Hunan Dongting Pharmaceutical Co., Ltd. and Shu Si produced by Suzhou Pharmaceutical Group Co., Ltd.
The CAGR of sales value of quetiapine surpassed 25% in Chinese sample hospitals from 2005 to 2012. Its growth rate has been declining slightly since 2010, but an annual growth rate of 10% is basically maintained. Quetiapine is now listed in Guidelines of Mental Illness Treatment in China. It is considered as a first-line drug to treat schizophrenia in Chinese market. Estimation indicates that the number of schizophrene in China will continue to rise in the next few years, leaving huge market space to grow for quetiapine.

Through this report, the readers can acquire the following information:
-Incidence of Schizophrenia in China
-Market Share of Major Quetiapine Manufacturers in China Sample Hospitals
-Sales price of Quetiapine in China Hospital Market
-Production Status of Quetiapine Generic Drug in China
-Major Quetiapine Manufacturers in China
-Prospect of China Quetiapine Market

The following enterprises and people are recommended to purchase this report:
-Anti-schizophrenia Medication Manufacturers
-Medical Institutions

To view the table of contents and know more details please visit Investigation Report on China Quetiapine Market, 2009-2018.

Investigation Report on China Pemetrexed Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Pemetrexed Market, 2009-2018. Pemetrexed, originally developed by Eli Lilly and Company, is a multi-targeted antimetabolite antitumor drug. This product is with huge growth potential in the market.
Approved by FDA in February 2004, pemetrexed is to treat unresectable malignant pleural mesothelioma with cisplatin. It is the first drug approved by FDA to treat the disease. In August 2004 pemetrexed was approved as a second-line drug for local or metastatic non-small cell lung cancer.
So far pemetrexed (brand name "Alimta") has been approved to more than 60 countries worldwide. The product has been a best seller of Eli Lilly and Company since it was launched, and its sales value keeps increasing year after year. The CAGR of sales value of pemetrexed was 50.6% from 2004 to 2011. The sales value was only USD 140 million in 2004 and reached USD 460 million in 2005. In 2011, it grew rapidly to USD 2.46 billion.
In the field of antitumor drugs in China, antimetabolic drug is one of the most common types among traditional anti-tumor chemotherapy drugs. Market size of pemetrexed in China has increased rapidly in recent years. The CAGR of its sales value exceeded 70% from 2006 to 2013.
Pemetrexed was approved to clinical use in China in 2004. It was approved to China in 2005 to treat malignant pleural mesothelioma. As a multi-targeted antimetabolite antitumor drug, pemetrexed can treat non-small cell lung cancer, pancreatic cancer and breast cancer with little side effect. Mechanism of pemetrexed is better than traditional antifolate drugs with great competitiveness in the field.
Hansoh Pharmaceutical and Qilu Pharmaceutical were approved to produce APIs and preparation of this drug respectively in 2005 and 2006. Seeing the great future in the market, a large number of manufacturers start to produce the drug. In 2005, many domestic manufacturers began to apply for the production of raw materials and injections. The competition becomes more intense every day.
From 2005 to 2010, Eli Lilly and Company occupied most of Chinese sample hospital market. However, Qilu Pharmaceutical and Hansoh Pharmaceutical has caught up with Eli Lilly and Company since 2011. The main reason is that drugs made within the country seize more market share with relatively low price. As a result, the market is mostly occupied by Qilu Pharmaceutical, Hansoh Pharmaceutical and Eli Lilly and Company.
By the end of 2013, over 10 manufacturers in China have been approved to produce pemetrexed in China by SFDA. It is estimated that the pemetrexed market in China will become increasingly competitive in the future. As environment pollution intensifies, population aging increases and lifestyle changes, incidence of cancer in China keeps rising, leading to rapid growth in antitumor drug market in China.

Through this report, the readers can acquire the following information:
-Market Share of Major Pemetrexed Manufacturers in Sample Hospitals in China
-Sales Price of Pemetrexed in China Hospital Market
-Major Pemetrexed Manufacturers in China
-Share of Pemetrexed in Different Dosage Forms in China Hospital Market
-Incidence of Cancer in China
-Manufacturing Schedule of Pemetrexed generic drug
-Prospect of China Pemetrexed Market

The following enterprises and people are recommended to purchase this report:
-Pemetrexed APIs and Finished Product Manufacturers
-Medical Institutions
-Investors/Research Institutes Focusing on Pemetrexed Market

To view the table of contents and know more details please visit Investigation Report on China Pemetrexed Market, 2009-2018.

Investigation Report on China Tacrolimus Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Tacrolimus Market, 2009-2018. Tacrolimus, also named as "FK506" and "FR-900506", was developed by Fujisawa Pharmaceutical Co., Ltd. (later became Astellas Pharma by merging with Yamanouchi Pharmaceutical Co., Ltd.). In June 1993, it was firstly approved to Japan with the trade name "Prograf". Tacrolimus is an immunosuppressive drug that is used mainly after allogeneic organ transplant to reduce the activity of the patient's immune system and so lower the risk of organ rejection. It was approved by the FDA in 1994. Tacrolimus is sold in markets of several countries and regions now. In 1998, tacrolimus preparation (injection and capsule) was approved to import into China.
Since then, tacrolimus has become a first-line clinical drug to reduce organ rejection after liver and kidney transplantation in China. The sales revenue is also increasing rapidly.
For immunosuppressant is used in transplantation, a relatively special field, it requires high technical standard and large amount of investment in new compound development. The drugs available at present are thus very monopolistic, among which tacrolimus is with the most promising future and highest market value.
Since organ transplantation volume in China is only second to that of the U.S.A., a great amount of immunosuppressant is needed. The Chinese government has chosen this drug as clinical-preferred basic immunosuppressant. In recent years, the clinical application of tacrolimus continues to expand. It can treat many autoimmune diseases and is approved effective for immune diseases without specific medicine such as rheumatoid arthritis, kidney cirrhosis syndrome, atopic dermatitis and lupus. Therefore, the future is bright for medical use of tacrolimus.

Through this report, the readers can acquire the following information:
-Market Share of Major Tacrolimus Manufacturers in China Sample Hospitals
-Sales price of Tacrolimus in China Hospital Market
-Major Tacrolimus Manufacturers in China
-Share of Tacrolimus in Different Dosage Forms in China Hospital Market
-Prospect of China Tacrolimus Market

The following enterprises and people are recommended to purchase this report:
-Tacrolimus APIs and Finished Product Manufacturers
-Medical Institutions
-Investors/Research Institutes Focusing on Tacrolimus Market

To view the table of contents and know more details please visit Investigation Report on China Tacrolimus Market, 2009-2018.

Investigation Report on China Enoxaparin Sodium Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Enoxaparin Sodium Market, 2009-2018. Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.
Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.
Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.
Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.
The CAGR of sales value of enoxaparin sodium injection in Chinese sample hospitals exceeded 17% from 2005 to 2012. On the one hand, incidence of vascular embolism keeps rising due to population aging in China. On the other hand, operations such as cardiovascular and cerebrovascular intervention develop rapidly. Followed up by the development of anticoagulation, antiplatelet and hypolipidemic treatment after stent surgery, antithrombotic drug market has been greatly expanded in China.
It is estimated that enoxaparin sodium market in China will rise significantly in the next few years.

Through this report, the readers can acquire the following information:
-Incidence of Thrombosis in China
-Market Share of Major Enoxaparin Sodium Manufacturers in China Sample Hospitals
-Sales price of Enoxaparin Sodium in China Hospital Market
-Production Status of Enoxaparin Sodium Generic Drug in China
-Major Enoxaparin Sodium Manufacturers in China
- Prospect of China Enoxaparin Sodium Market

The following enterprises and people are recommended to purchase this report:
-Anti-clotting Drugs Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Anti-clotting Drug Market

To view the table of contents and know more details please visit Investigation Report on China Enoxaparin Sodium Market, 2009-2018.

Investigation Report on China Rituximab Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Rituximab Market, 2009-2018. Rituximab (trade names "MabThera" by Roche, "Rituxan" by Genetech) is a chimeric monoclonal antibody against the protein CD20 approved in 1997 to treat tumor. It is very effective and shows good tolerance in the treatment of B-cell lymphoma. As people understand more about B-cell and its action mechanism, it is acknowledged that besides B-cell malignancies rituximab can also treat autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and idiopathic thrombocytopenic purpura. Global sales revenue of rituximab is USD 5,034 million, USD 6,140 million and USD 7,143 million from 2010 to 2012 respectively.
Statistics shows that incidence of non-Hodgkin lymphomas in China has increased steeply from 20/1,000,000 at the end of the 20th century to 70/1,000,000 at present. Autoimmune diseases can harm central nervous system and organs such as lung, liver and kidney, leading to organ dysfunction and even organ failure. All of them can be life-threatening. Statistics shows that there are approximately 30 to 40 million people suffering from autoimmune diseases in China. Such high incidence should be taken seriously by the public.
By the first quarter of 2014, there were no products from local manufacturers on the market, which was completely occupied by Roche. Early 2014, monoclonal antibody drug "recombinant human-mouse chimeric anti-CD20 monoclonal antibody injection" produced by Hisun was approved clinical. It is a generic drug of Roche's monoclonal antibody "Rituximab". Five manufacturers in China have reported clinical use of rituximab generic drug. It is estimated that more generic drugs will go on the market in the next few years. According to investigation on certain sample hospitals in China, the CAGR of sales value of rituximab surpassed 35% from 2005 to 2012. Rituximab is expected to have huge room to grow in future Chinese market.

Through this report, the readers can acquire the following information:
-Market Share of Major Rituximab Manufacturers in China Sample Hospitals
-Sales Price of Rituximab in China Hospital Market
-Market Share of Rituximab by Dosage Form in China Hospital Market
-Incidence of Autoimmune Diseases in China
-Manufacturing Schedule of Rituximab Generic Drug
-Prospect of China Rituximab Market

The following enterprises and people are recommended to purchase this report:
-Monoclonal Antibody APIs and Finished Product Manufacturers
-Medical Institutions
-Investors/Research Institutes Focusing on Monoclonal Antibody Market

To view the table of contents and know more details please visit Investigation Report on China Rituximab Market, 2009-2018.

Investigation Report on China Telmisartan Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Telmisartan Market, 2009-2018. According to statistics from WHO, one-third of the world's adults have high blood pressure. Death toll of this disease equals to half of the total number caused by stroke and heart attack.
Angiotensin II receptor antagonist (ABR) is an important product among various antihypertensive drugs. Telmisartan was firstly developed by Boehringer Ingelheim and approved to the U.S. market for the first time in 1999 with the trade name "Micardis". It is a once-daily oral medication for the treatment of essential hypertension. In the same year, telmisartan was jointly sold as "Micardis" by Boehringer Ingelheim and "Pritor" by Glaxo Wellcome in Germany. It was approved to market in December 1999 in Philippines. In 2000, it was approved to market in Australia, Belgium and Britain. Glaxo Wellcome owns the marketing right worldwide except in Japan and the U.S. The company is also developing compound preparation of telmisartan and other hypertension drugs. Abbott Laboratories holds the sales license of this product in the United States. At the end of 2000, Boehringer Ingelheim introduced raw material and preparation of telmisartan into Chinese market. Several telmisartan generic drugs have also been approved to Chinese market in succession since 2004.
Statistics shows that incidence of hypertension among Chinese people aged 15 and above is 24%. There are more than 260 million hypertension patients in the country, with at least one hypertension patient among 5 adults. The prevention and cure for hypertension in China is faced with very tough challenges. Less than 40% of hypertension patients are aware of their illness, while only one-fourth of them are under proper management. Among those who are under management, 60% are willing to take medicines, while only 50% of them have their blood pressure under control. According to Investigation, more than CNY 40 billion is annually spent on hypertension treatment in China. In 2013, market size of antihypertensive prescription drug in China exceeded CNY 20 billion, increased more than 15% YOY. This has shown great potential of Chinese market.
The CAGR of sales value of telmisartan surpassed 65% in Chinese sample hospitals from 2005 to 2010. Its growth rate dropped slightly in 2011, but an annual growth rate of 10% is still maintained. From the perspective of sales revenue, original drug produced by Boehringer Ingelheim has seized most of Chinese telmisartan market while other market share is occupied by generic drugs produced by manufacturers such as Yichang Changjiang Pharmaceutical Co., Ltd. and Beijing Double-Crane Pharmaceutical Co., Ltd. It is estimated that incidence of hypertension in China will continue to rise year by year due to improvement of living standard, changes of eating habit, increasing stress of life and lack of health awareness. As Chinese people's incomes increase, the affordability of antihypertension drugs increases. Estimation shows that market size of telmisartan in China will keep rising in the next few years.

Through this report, the readers can acquire the following information:
-Market Share of Telmisartan Produced by Different Manufacturers in China Hospital Market
-Sales price of Telmisartan in China Hospital Market
-Major Telmisartan Manufacturers in China
-Share of Telmisartan in Different Dosage Forms in China Hospital Market
-Prospect of China Telmisartan Market
The following enterprises and people are recommended to purchase this report:
-Antihypertensive APIs and Finished Product Manufacturers
-Medical Institutions
To view the table of contents and know more details please visit Investigation Report on China Telmisartan Market, 2009-2018.

2014 Deep Research Report on Global and China Salicylic Acid (SA) Industry

Reportstack has announced a new market research publication on 2014 Deep Research Report on Global and China Salicylic Acid (SA) Industry which provides a basic overview of the industry including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered.

Global and China Salicylic Acid Industry Research Report 2013 also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and price cost production value gross margins are discussed.

A key feature of this report is it focus on major industry players, providing an overview, product specification, product capacity, production price and contact information for Global Top15 companies. This enables end users to gain a comprehensive insight into the structure of the international and Chinese Salicylic Acid industry. Development proposals and the feasibility of new investments are also analyzed.

Companies and individuals interested in the structure and value of the Salicylic Acid industry should consult this report for guidance and direction.

Companies Mentioned:
Novacyl (Novacap), Hebei Jingye, Zhenjiang Gaopeng, Shandong Xinhua Longxin,  Huayin Jinqiancheng.

To view the table of contents and know more details please visit 2014 Deep Research Report on Global and China Salicylic Acid (SA) Industry.

2014 Deep Research Report on Global and China VAE Emulsion Industry

Reportstack has announced a new market research publication on 2014 Deep Research Report on Global and China VAE Emulsion Industry which provides a basic overview of the industry including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered.
2014 Deep Research Report on Global and China VAE Emulsion Industry also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and gross margins are discussed.
A key feature of this report is it focus on major industry players, providing an overview, raw materials analysis, product capacity, production price and contact information. This enables end users to gain a comprehensive insight into the structure of the international and Chinese VAE Emulsion industry. Development proposals and the feasibility of new investments are also analyzed. Companies and individuals interested in the structure and value of the VAE Emulsion industry should consult this report for guidance and direction.

Companies Mentioned:
Wacker Chemie AG, Celanese AG, Dairen Chemical Corporation, Showa Highpolymer, Beijing Eastern Petrochemical, Wanwei Group, Shanxi Sanwei.

To view the table of contents and know more details please visit 2014 Deep Research Report on Global and China VAE Emulsion Industry.

Investigation Report on China Insulin Glargine Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Insulin Glargine Market, 2009-2018. With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.
According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.
It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.
Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.
In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.
Based on research about certain sample hospitals in China, the CAGR (compound annual growth rate) of sales value of insulin glargine in Chinese sample hospital market exceeded 70% from 2005 to 2013. Human insulin is produced through genetic engineering methods, so a relatively high threshold of production technology is formed. Compared with other genetic engineering drugs, insulin is of large demand and comparatively cheap, so manufacturers have to attain an industrial production of large scale, low cost and mature technology before gaining profit. At present, Chinese market is mainly occupied by LANTUS produced by Aventis Behring GmbH and Basalin by Gan & Lee Pharmaceuticals. However, changes of global market pattern are expected to happen in the next few years. On the one hand, in the global market, MSD Co., Ltd. is working with Samsung Bioepis to develop LANTUS. The two companies declared on Feb 10, 2014 that the product will soon launch the third phase clinical trial on Type I and Type II diabetes. Presently, LANTUS generic drug produced by Eli Lilly and Company has come to the late-stage clinical trials. On the other hand, in Chinese market, some local businesses are also hastening the development of LANTUS generic drug.
As Chinese people's living standard improves and lifestyles change, incidence of diabetes continuously goes up, resulting in the year-after-year expanding of diabetes drug market in the country. According to investigation, total sales value of diabetes drug market in China surpassed CNY 18 billion in 2013. In China, the second-generation recombinant human insulin is still the market mainstream. However, as the third-generation insulin products are more technically advanced comparing with the second-generation by diminishing certain defects and shortening curing time effectively, it is expected to replace the second-generation in the near future. As a product with most growth potential among the three generations of insulin products in China, insulin glargine is expected to get more and more attention.

Through this report, the readers can acquire the following information:
-Market Share of Major Insulin Glargine Manufacturers in Sample Hospitals in China
-Sales Price of Insulin Glargine in Hospital Market in China
-Major Insulin Glargine Enterprises in China
-Market Share of Insulin Glargine by Dosage Form in Hospital Market in China
Prospect of China Insulin Glargine Market

The author recommends the report to the following:
-Insulin Glargine API and Finished Product Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Insulin Glargine Market

To view the table of contents and know more details please visit Investigation Report on China Insulin Glargine Market, 2009-2018.

Investigation Report on China Bevacizumab Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Bevacizumab Market, 2009-2018. Bevacizumab is an important kind of remedy for metastatic colon cancer, which belongs to humanized anti-VEGF monoclonal antibody. Approved by FDA, bevacizumab came into the market in 2004, with the brand name of "Avastin". Its main mechanism is to inhibit the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation through specific binding so as to stop or delay growth of blood vessels in tumor, disconnect the delivery of oxygen and other nutrition necessary in tumor cells' growth, as well as to improve the effect of chemotherapy remedy. Public data shows that the global sales value of bevacizumab in 2012 exceeded USD 6.3 billion, ranking the fourth among the 10 best selling monoclonal antibody drugs.
As Chinese economy develops rapidly, Chinese people's lifestyle is changing tremendously. With the aging level increasing, environment pollution worsening, the incidence of cancer in China keeps rising. Statistics indicate that the annual increase of cancer patients in China takes up over 20% of the global, making China a capital antitumor remedy market of the world. Shanghai Roche Pharmaceuticals Ltd. declared on May 7, 2010 that its bevacizumab injection (brand name "Avastin") was approved by the FDA for curing metastatic colorectal cancer. It is the official entry of the world's first angiogenesis inhibitor into Chinese market. The market investigation manifests that the sales value of Avastin in certain Chinese sample hospitals in 2010 was merely CNY 10 million, growing rapidly. It broke through CNY 200 million in 2013.
There have been some generic drug manufacturers developing bevacizumab around the world. At the end of 2013, Huahai Pharmaceutical in China announced that its bevacizumab generic drug developed with Oncobiologics Company was approved to conduct the first clinical trial in the European Union.
Some study declared that the combination of bevacizumab and chemotherapy can prolong overall survival time of advanced cervical cancer patients. This result indicates the possibility of this remedy with the annual sales value of USD 1 billion to treat cervical cancer.

Through this report, the readers can acquire the following information:
- Market Share of Major Bevacizumab Manufacturers in Sample Hospitals in China
- Sales price of Bevacizumab in Hospital Market in China
- Share of Bevacizumab in Different Dosage Forms in Hospital Market in China
- Incidence of Cancer in China
- Manufacturing Schedule of Bevacizumab generic drug
- Prospect of China Bevacizumab Market

The author recommends the report to the following:
- Manufacturers of Crude and Finished Monoclonal Antibody Remedy
- Medical Institutions
- Investors/Research Institutes Focusing on Bevacizumab Market

To view the table of contents and know more details please visit Investigation Report on China Bevacizumab Market, 2009-2018.

2014 Deep Research Report on Global and China Automotive Oxygen Sensor Industry

Reportstack has announced a new market research publication on 2014 Deep Research Report on Global and China Automotive Oxygen Sensor Industry which is a professional and in-depth study on the current state of the Automotive Oxygen Sensor industry in Global and China.

The report provides a basic overview of the industry including definitions, applications and industry chain structure. Global market analysis and Chinese domestic market analysis are provided with a focus on history, developments, trends and competitive landscape of the market. A comparison between the international and Chinese situation is also offered.

Global and China Automotive Oxygen Sensor Industry Research Report 2013 also focuses on development policies and plans for the industry as well as a consideration of a cost structure analysis. Capacity production, market share analysis, import and export consumption and gross margins are discussed.

A key feature of this report is it focus on major industry players, providing an overview, raw materials analysis, product capacity, production price and contact information. This enables end users to gain a comprehensive insight into the structure of the international and Chinese Automotive Oxygen Sensor industry. Development proposals and the feasibility of new investments are also analyzed.

Companies Mentioned:
Bosch, Delphi, NTK/NGK, Denso, Kefico, Paile, Pucheng Sensors and Volkse

To view the table of contents and know more details please visit 2014 Deep Research Report on Global and China Automotive Oxygen Sensor Industry.

Investigation Report on China Montelukast Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Montelukast Market, 2009-2018. There are over 30 million people suffering from seasonal asthma of different levels worldwide, and the situation is worse in deeply contaminated countries and regions with high tobacco consumption. Asthma and allergic rhinitis are both very common diseases in the world today. As the atmosphere becomes more seriously contaminated, incidence of these diseases increases year by year.
Montelukast, developed by MSD Co., Ltd., is widely used in curing allergic rhinitis and asthma. Montelukast is a CysLT1 antagonist that blocks the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1 in the lungs and bronchial tubes by binding to it. This reduces the bronchoconstriction otherwise caused by the leukotriene and results in less inflammation.
In 1998, montelukast sodium tablets (10mg) and chewable tablets (5mg) were approved by FDA to the market with the trade name "Singulair". In 2000 and 2002, montelukast chewable tablets (4mg) and montelukast granules (4mg) were approved to the market in turn. They are mainly used in prevention and long-term treatment of asthma of adult and children aged two and above.
Patent of Singulair in U.S. expired on August 3, 2012. Hereafter, FDA approved over 10 manufacturers' applications for their generic drugs to the market. Among them, Teva Pharmaceutical Industries Limited launched tablets, chewable tablets and oral granules while Dr. Reddy's Laboratories Ltd. launched tablets and chewable tablets. In 2012, due to the generic drug intrusion, sales revenue of Singulair produced by MSD Co., Ltd. dropped to USD 3,853 million, decreased by 30%.
In 1999, montelukast chewable tablets (5mg) and tablets (10mg) produced by MSD Co., Ltd. were allowed to enter China with the trade name "Singulair". Hereafter, montelukast chewable tablets (4mg) and granules (4mg) were permitted into Chinese market sequentially. Generic montelukast tablets (10mg) and chewable tablets (5mg) produced by Sichuan Otsuka Pharmaceutical Co., Ltd. were approved to the market in 2006 with the trade name "Bai Sanping". Mudanjiang Hengyuan Pharmaceutical Co., Ltd. was the first manufacturer that acquired approval of montelukast sodium raw material production in 2006. In 2008, Lunan Better Pharmaceutical Co., LTD. was given the approval of montelukast tablets (10mg) and chewable tablets (5mg). In addition, many drug manufacturers such as YZJ Group and Beijing Winsunny Pharmaceutical Company Limited have applied for generic drugs production.
According to investigation on certain sample hospital market in China, the CAGR of sales value of montelukast surpassed 45% from 2005 to 2010. As more competitors entered the market, Chinese montelukast market growth has slowed down since 2011. However, an annual growth rate of 10% is still maintained.
Statistics shows that there are over 30 million asthma patients and 30 to 40 million people suffering from allergic rhinitis in China. As the environment becomes worse in China, more people will suffer from asthma and allergic rhinitis. In China, montelukast is considered as one of the best anti-asthma drugs. Consequently, it is expected to have huge market potentials.

Through this report, the readers can acquire the following information:
-Incidence of Respiratory Disease in China
-Market Share of Major Montelukast Manufacturers in Sample Hospitals in China
-Sales price of Montelukast in China Hospital Market
-Production Status of Montelukast Generic Drug in China
-Major Montelukast Manufacturers in China
-Share of Montelukast in Different Dosage Forms in China Hospital Market
-Prospect of China Montelukast Market

The author recommends the report to the following:
-Montelukast APIs and Finished Product Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Respiratory Drug Market

To view the table of contents and know more details please visit Investigation Report on China Montelukast Market, 2009-2018.

Investigation Report on China Budesonide Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Budesonide Market, 2009-2018. Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere becomes more and more seriously contaminated, incidence of these diseases increases year by year.
Budesonide inhalation suspension (trade name "Pulmicort Respules") developed by Astra Zeneca was approved to market by FDA for asthma treatment in August 2000. It obtained import approval in China in November 2001. Statistics shows that there are more than 30 million asthma patients and over 0.3 billion people suffering from allergic rhinitis in China. According to investigation on certain sample hospital market in China, the CAGR of sales value of budesonide surpassed 30% from 2005 to 2010. Since 2011, market growth has slowed down, but it still maintains an annual growth rate of 18%.
In April 2013, the patent protection of asthma drug "Pulmicort Respules" produced by Astra Zeneca was sentenced invalid in an U.S. regional court. Industry insiders think that this has paved the way for generic drug to occupy the market.
According to market investigation, budesonide products in Chinese market are still mainly imported drugs from Astra Zeneca, but there are already some Chinese enterprises, such as Lunan Better Pharmaceutical Co., Ltd., Humanwell Healthcare (Group) Co., Ltd. and Shanghai Sine Promod Pharmaceutical Co., Ltd., producing budesonide APIs and finished drugs.
On January 15, 2013 Santarus, Inc. announced that FDA has ratifies the usage of Uceris sustained release tablets in alleviating symptoms of mild - moderate active ulcerative colitis. Uceris is a new drug developed by Santarus, Inc. and Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. This is a new oral tablet, and its main ingredient is budesonide.
As Chinese economy develops and its environment worsens, the number of asthma and allergic rhinitis patients in China will continue to rise in the next few years. Furthermore, more indications may emerge in China. Consequently, market size of budesonide in China will therefore continue to grow.

Through this report, the readers can acquire the following information:
-Incidence of Respiratory Disease in China
-Market Share of Major Budesonide Manufacturers in Sample Hospitals in China
-Sales price of Budesonide in Hospital Market in China
-Production Status of Budesonide Generic Drug in China
-Major Budesonide Manufacturers in China
-Share of Budesonide in Different Dosage Forms in China Hospital Market
-Prospect of China Budesonide Market

The author recommends the report to the following:
-Budesonide Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Respiratory Drug Market

To view the table of contents and know more details please visit Investigation Report on China Budesonide Market, 2009-2018.

Investigation Report on China Duloxetine Market, 2009-2018

Reportstack has announced a new market research publication on Investigation Report on China Duloxetine Market, 2009-2018. Depression is a common mood disorder that belongs to high-incidence mental diseases worldwide. Its main clinical features are a state of low mood and aversion to activity, and sometimes even suicidal thoughts or behaviors.
According to statistics from World Health Organization (WHO), depression is one of the most disabling diseases in the world today with over 0.3 billion sufferers worldwide. Because there are 10 to 20 million patients with suicidal thoughts every year in the world, it is said that 21 century is a "Century of Depression". China is going through social transformation, which is also a period with high incidence of psychological problems. Statistics shows that there are more than 30 million depression patients now in China, of which over 80% have never been treated because of low income or other issues. Depression patients take up 50% to 70% of suicides and attempted suicides in China. Obviously, depression has become a major social problem in China.
Since Eli Lilly and Company first launched duloxetine (brand name "Cymbalta") in August 2004, its sales revenue has been continually increasing, which nearly reached USD 5 billion in 2012.
The success of duloxetine sales also comes from its persistent exploration and study into indications. It is approved to treat adult depression by FDA and EU in August and September 2004 respectively. In September 2004 FDA approved its treatment for new important indications of diabetic peripheral neuropathic pain, making it the first drug approved for these diseases. In August 2004 duloxetine was also approved to cure women patients who lack effective treatment of moderate - severe stress urinary incontinence symptoms. Duloxetine was also authorized to treat fibromyalgia in June 2008 and chronic musculoskeletal pain in November 2010 by FDA. It is this constant innovation that makes duloxetine produced by Eli Lilly and Company best selling antidepressant worldwide. Before patent of duloxetine expired at the end of 2013, almost all famous general drug manufacturers planed to seize this great opportunity. In recent years, some pharmaceutical companies have earned provisional approvals issued by FDA.
Many manufacturers did not report the production of raw materials and preparation until 2005. However, only Shanghai Zhongxi Pharmaceutical Co., Ltd. successfully produced generic drug before duloxetine was under administrative protection, and was given the production approval of enteric-coated capsules and enteric-coated tablets. In present Chinese market, only Eli Lilly and Company and Shanghai Zhongxi Pharmaceutical Co., Ltd. are approved to sell duloxetine products. Yet in July 2013, some other manufacturers received drug registration approval of duloxetine APIs and enteric-coated tablet issued by FDA, whose products are expected to go on the market in 2014.
In China, antidepressants are still niche products. According to CRI's investigation, market size of antidepressant in China was less than CNY 4 billion in 2013. Main cause of current situation is society's lack of understanding of depression, which discourages patients from psychiatric treatment because of the prejudice. Another reason is people's lack of knowledge about depression. When depression occurs, people may consider it as emotional problems and miss the best time for medical treatment, leading to further deterioration. Low market demand leads to slow development of antidepressants by drug manufacturers. However, as Chinese society develops and people's living standard improves, Chinese people would require spiritual life of higher quality, which bestows antidepressant market a promising future. Market size of duloxetine therefore will soon increase rapidly.

Through this report, the readers can acquire the following information:
-Incidence of Depression in China
-Market Share of Major Duloxetine Manufacturers in Sample Hospitals in China
-Sales price of Duloxetine in Hospital Market in China
-Production Status of Duloxetine Generic Drug in China
-Major Duloxetine Manufacturers in China
-Share of Duloxetine in Different Dosage Forms in China Hospital Market
-Prospect of China Duloxetine Market

The author recommends the report to the following:
-Antidepressant APIs and Finished Product Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on China Antidepressant Market

To view the table of contents and know more details please visit Investigation Report on China Duloxetine Market, 2009-2018.

Global High Performance Computing (HPC) Market 2014-2018

Reportstack has announced a new market research publication on Global High Performance Computing (HPC) Market 2014-2018The following companies are the key players in Global High Performance Computing (HPC) Market: Cray Inc., Dell Inc., Hewlett-Packard Co., and IBM Corp.

“HPC as a Service is fast gaining in popularity in the Global HPC market since it offers high performance on demand and a scalable HPC computing environment. The computing resources provided by the service providers can vary in power, technology, and latency. HPCaaS helps optimize the environment for HPC; with the help of HPCaaS, enterprises can solve the problem of surge capacity for time-critical analysis by having resources available as and when needed. HPCaaS has a centralized system so that enterprises can minimize the impact of remote collaboration issues. HPCaaS is designed to leverage the financial benefits of a managed solution, cloud, while providing an infrastructure focused around HPC. This gives enterprises the capability to meet an organization's research and engineering compute requirements without incurring the capital and operational costs associated with setting up an in-house HPC cluster.”

According to the report, one of the major drivers in this market is the increasing need to maintain the huge amounts of data produced. The need to maintain and analyze the data that is generated from various sources is fueling the demand for HPC solutions among enterprises. HPC solutions help organizations to store the data, speed up the calculations, and take strategic decisions based on the outcomes.

Further, the report states that the high implementation cost of HPC resources is one of the major challenges confronting this market. The deployment of HPC solutions is an expensive process, which needs a detailed and usually costly process of defining requirements. This increases the criticality of the process because, once deployed, further costs may be incurred if any changes have to be made.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150211/global-high-performance-computing-hpc-market-2014-2018.html

Global Transformer Monitoring Solutions Market 2014-2018

Reportstack has announced a new market research publication on Global Transformer Monitoring Solutions Market 2014-2018. The following companies are the key players in Global Transformer Monitoring Solutions Market: ABB Ltd., Alstom SA, GE Co., Schneider Electric SA, and Siemens AG.

“In order to sustain and compete in the overall market, vendors are increasingly developing new and advanced monitoring systems with enhanced functionalities. Such smart monitoring systems include a DGA, a built-in simulator, and expert system software, which enable the monitoring process to be carried out more effectively and efficiently. Therefore, the development of next-generation transformer monitoring systems is expected to drive the growth of the market during the forecast period.”

According to the report, the main driver is the increasing demand for electricity across the globe. The increasing need for a continuous power supply has led to the setting up of a large number of power stations or substations that require the installation of step-up and step-down power transformers, which need continuous monitoring to detect and identify any system failure.

Further, the report states that the high price of transformer monitoring systems is one of the major challenges in the market. The installation of transformer monitoring systems requires a huge investment, which makes end-users reluctant to adopt monitoring systems.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150212/global-transformer-monitoring-solutions-market-2014-2018.html

Global Wireless Gigabit Market 2014-2018

Reportstack has announced a new market research publication on Global Wireless Gigabit Market 2014-2018The following companies are the key players in Global Wireless Gigabit Market: Broadcom Corp., Intel Corp., Qualcomm Atheros Inc., Panasonic Corp. and MediaTek Inc.

“In the beginning of 2013, the IEEE approved a new wireless specification that could be used in devices to deliver tri-band networking and support emerging WiGig technology. The approval is considered a lucrative solution to open new avenues of application for the service providers, felicitating high speed up to 7Gbps on the unlicensed 60GHz radio spectrum band. The standard association claimed the new development will offer around 10 times the rate of speeds offered through the incumbent 802.11n standard, which uses the 2.4GHz and 5GHz spectrum bands. The 802.11ad (or WiGig) will offer faster networking because of the low extent of interception and interference of its shorter range in the 60GHz band. Due to the revolution in the data-centric applications, the tri-band devices can support up to 7Gbps speed enabling high-speed file transfers and WiGig docking technology, which can connect portable user devices to a display the moment it is placed. During the forecast period, the market will be flooded with tri-band supported devices, driving the Global WiGig market.”

According to the report, there are several factors that drive the growth of the Global WiGig market; one of them is the unrelenting demand for mobile data applications and hence the supporting devices. The steady increase in data traffic caused by smart devices plays a major role in driving the demand for the market.

Further, the report states that one of the main challenges is the omnipresence of Wi-Fi-enabled devices. The Wi-Fi standard has been around for more than two decades, and has carved a strong position in the Global Networking market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit http://www.reportstack.com/product/150213/global-wireless-gigabit-market-2014-2018.html